^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Glioblastoma

    Related cancers:
    1d
    ONC206-001: Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms (clinicaltrials.gov)
    P1, N=102, Recruiting, Jazz Pharmaceuticals | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial primary completion date • First-in-human
    |
    JZP3507
    1d
    PNOC017: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (clinicaltrials.gov)
    P1, N=78, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH2 mutation
    |
    temozolomide • Partruvix (pamiparib)
    1d
    FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma (clinicaltrials.gov)
    P=N/A, N=7, Completed, Jonsson Comprehensive Cancer Center | N=50 --> 7 | Trial completion date: Aug 2026 --> Jan 2025 | Trial primary completion date: Aug 2025 --> Jan 2025 | Recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    2d
    ReVoGlio: Vortioxetine for Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=78, Not yet recruiting, University of Zurich
    New P2 trial
    |
    temozolomide
    2d
    Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. (clinicaltrials.gov)
    P1, N=18, Recruiting, Henry Ford Health System | Trial completion date: Oct 2026 --> Dec 2027 | Trial primary completion date: Oct 2025 --> Jan 2027
    Trial completion date • Trial primary completion date
    2d
    Expression of DNA-damage response genes after exposure to high LET particles used in BNCT in glioblastoma cells with altered radiosensitivity. (PubMed, Sci Rep)
    These findings highlight the pivotal role of DNA-PKcs status in shaping the DNA damage response and radiosensitivity of glioblastoma cells. Targeting compensatory repair pathways in DNA-PKcs-deficient tumors may offer novel strategies for radiosensitization in glioblastoma therapy.
    Journal
    |
    PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
    2d
    Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel. (PubMed, Nat Commun)
    This approach represents a real-time surrogate biomarker for treatment response for a disease where imaging-based assessment of response has not been shown to be reliable. Future prospective validation is warranted.
    Journal
    |
    ANXA5 (Annexin A5)
    |
    paclitaxel
    2d
    The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Mayo Clinic
    New P2 trial
    2d
    SENIPERA: Senicapoc and Perampanel for Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Aarhus University Hospital
    New P1 trial
    |
    Fycompa (perampanel)
    3d
    Single-Cell Transcriptomic Profiling of GL261 Glioblastoma Cells Reveals Gene Expression Signatures Underlying Tumorigenicity. (PubMed, Cell Mol Neurobiol)
    We found that P2RX7, MMP15 and MMP16 are upregulated in neurosphere cells, indicating a potential role for these genes in tumor formation. Together these results reveal global transcriptional profiles of GL261 cells, establish a resource for further scRNA-Seq-based analyses, and give insight into gene expression changes relevant to glioblastoma tumor development.
    Journal
    |
    MMP16 (Matrix Metallopeptidase 16)
    3d
    Continuous electrochemical H2O2 delivery for cancer cell treatment. (PubMed, J Mater Chem B)
    This novel approach of electrochemical H2O2 delivery holds significant potential for enhancing targeted cancer therapies, offering a controllable, precise, and efficient method for inducing tumor cell death while minimizing damage to healthy tissues. These results showcase the remarkable ability of PEDOT electrodes as a reliable electrocatalytic source of on-demand H2O2 in electrochemically-challenging biological environments.
    Journal
    |
    CAT (Catalase)
    3d
    Claudins proteins in brain tumors: expression patterns and therapeutic target. (PubMed, Biochem Med (Zagreb))
    Presented results suggest that CLDNs may serve as biomarkers for diagnosis and prognosis as well as therapeutic targets in CNS tumors. Further investigation is essential to clarify their clinical relevance and therapeutic potential.
    Review • Journal
    |
    CLDN1 (Claudin 1) • CLDN3 (Claudin 3) • CLDN5 (Claudin 5)